If cash flow is not growing / compounding - why do you expect the share price to make newer ATHs ?

Ultimately, the stock price is a function of underlying business and the quality of cash flows

"Quality vs Quantity" of cash matters. Small and Mid Pharma have outperformed Large!

More from Sajal Kapoor

More from Uvlearnings

Research in CDMO/APIs is never a slam dunk. It may take ages to yield results. CEP filings can be lumpy as a result. As I wrote last year (link below), Hikal has been consistently sacrificing operating profits for a sustainable future. Best is ahead 🎥 🍿

https://t.co/hItmOud8Pm

You May Also Like